Compare ADT Inc (ADT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Sana Biotechnology Inc — how do they compare? ADT Inc trades at $7.37 (market cap $5.44B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: ADT Inc is far larger — about 4.8× Sana Biotechnology Inc's market cap, and ADT Inc pays a 2.95% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ADT | SANA | |
|---|---|---|
Market Cap | $5.44B | $1.13B |
Sector | Industrials | Health |
52-Week High | $8.85 | $5.92 |
52-Week Low | $6.30 | $2.68 |
Enterprise Value | $13.13B | $1.05B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.33, down 2.4% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.23, beating estimates, and maintains strong cash flow. Valuation ratios appear attractive with a P/E of 10.35 and EV/EBITDA of 4.93. Recent news highlights a Zacks upgrade to Buy and institutional stake increases.
Outlook is positive due to consistent earnings beats and solid profitability, but risks include high debt levels and competitive pressures. Analysts are generally bullish, with 47% recommending Buy. The stock offers value with growth potential from AI integration and shareholder returns via dividends and buybacks.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
